ILMN Illumina Inc
Company Analysis
Latest News
Illumina attracts institutional buyers despite director’s $145 million stock sale
Several institutional investors recently established new positions in Illumina. Patient Capital Management LLC acquired 345,314 shares valued at approximately...
🟢 Illumina is trading 5% up today after broad biotech rally
Illumina is trading now at $215.64, up 5.19%, following investor enthusiasm after Moderna and Merck’s positive Phase 3 personalized mRNA cancer-vaccine results...
🟢 Illumina rises 5.8% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Illumina Completes $300M Public Offering of 4.950% Notes Due 2029
Illumina announced the completion of a public offering of $300 million in senior notes. The company intends to use the net proceeds, combined with cash on...
Illumina Director Sells $148 Million Stake in Year’s Largest Insider Trade
Illumina, Inc. Independent Director Keith Meister sold a block of shares worth approximately $148 million. The transaction was executed at a price of roughly...
Illumina Reaches No-Payment Settlement with Icahn in GRAIL Acquisition Lawsuit
Illumina, along with several current and former directors, has entered into a settlement agreement to dismiss the lawsuit filed by Icahn Partners LP concerning...
🔴 Illumina is trading 5% down today with no clear company-specific catalyst
Illumina is trading at $188.77 (-4.79%) after no clear company-specific catalyst emerged in August 6, 2026 coverage. • The latest confirmed company event was...
🔴 Illumina is trading 4.1% down today on profit-taking and broader biotech weakness
Illumina is trading 4.1% down at $196.74 on post-earnings profit-taking and broader biotech sector weakness. • The company beat Q2 expectations and raised its...
Illumina's second quarter revenue of $1.16B beats estimates, prompting a raised full-year 2026 outlook.
Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% year-over-year, and non-GAAP diluted EPS of $1.31. These results exceeded analyst...
🟢 Illumina is trading 4.1% up today ahead of Q2 earnings release
Illumina is trading 4.1% up at $202.76 as investors position themselves ahead of the company’s Q2 2026 earnings release scheduled for after the market...
Illumina Inc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Illumina is projected to report Q2 2026 revenue of $1.12 billion and EPS of $1.23, as the current stock price of $128.45 seeks to close the gap toward the...
🔴 Illumina is trading 5.3% down today on broad tariff concerns and a tech-led pullback
Illumina is trading 5.3% down at $186.41 in pre-market action as markets digest new broad U.S. tariffs and a tech-led retreat. • The decline follows a...
🟢 Illumina is trading 4.08% up today as shares gain momentum following new executive appointments
Illumina is trading at $195.47 (+4.08%) today. • The company announced the appointments of Mike Sullivan as Chief Commercial Officer and Julie Coletti as...
🔴 ILMN is trading 5.2% down today on a post-earnings pullback following a recent guidance-driven surge
ILMN is trading 5.2% down at $181.71 in pre-market as investors reassess the stock's valuation following a significant rally triggered by its latest financial...
🔴 ILMN Shares Fall 5% in After-Hours Trading Despite Piper Sandler Price Target Raise
• Illumina (ILMN) is trading at $175.10, down approximately 5% in after-hours trading, retracing from its recent multi-day rally. • This decline occurs despite...
🟢 ILMN extends move to 5.0% up
ILMN is trading at $184.66, up 5.0% versus the comparison close of $175.83 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 ILMN is trading 4.1% up today after Guggenheim and Piper Sandler raise price targets
• ILMN is trading 4.1% up now at $182.98, with gains driven by fresh bullish analyst commentary from Guggenheim and Piper Sandler. • Both Guggenheim and Piper...
🟢 Illumina Inc is trading 4.19% up
ILMN is trading at $182.43, up 4.19%.
🟢 ILMN extends move to 6.2% up
ILMN is trading at $175.12, up 6.2% versus the comparison close of $164.93 during regular trading. This is a price-movement alert; no separate company-specific...
Illumina Appoints Eli Lilly's Chief Scientific Officer to its Board of Directors
Illumina announced it has appointed Dr. Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026. In connection with the appointment, the...